196.8K
Downloads
771
Episodes
Content for investors by investors . These are audio podcast versions of our videos. Sometimes slides are referred to, to view as videos go to www.piworld.co.uk
Episodes
Monday Mar 16, 2020
Monday Mar 16, 2020
By Cathal Friel, Exec Chair
Friel gives an overview of Open Orphan, how it was formed, the business, hVIVO and its work with virus testing, plus comments on COVID-19.
Introduction – 00:18
Open Orphan management – 03:00
History and acquisitions – 04:15
High value & longer-term contracts – 08:32
Open Orphan – 09:22
Genomic database – 10:13
hVIVO viral challenge studies, etc – 10:33
Cross-selling – 17:45
Pipeline – 18:42
Cost reduction programme – 19:42
Development assets – 20:01
COVID-19 – 21:12
Q&A – 29:15
Open Orphan plc, formerly Venn Life Sciences Holdings plc, is engaged in the pharma services business. The Company is also engaged in building an orphan drug consulting services platform that helps pharma companies commercialize their products in Europe. The Company consists of four elements: a European clinical research organization and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians, and a Health Data Platform. The Company provides fragmented orphan drug services. The Company acquires and consolidates series of orphan drug services companies. It also provides digital data platforms to support companies in research & development and commercialization.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.